SBRI Healthcare Awards Funding for Phase 2 Development Program - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

SBRI Healthcare Awards Funding for Phase 2 Development Program

SBRI Healthcare, a Department of Health-funded initiative to develop innovative solutions that address unmet health needs, announced the three companies awarded phase 2 development funding in the SBRI Medicines Management competition.

From five companies awarded phase 1 funding in October 2012, three have demonstrated best value and greatest technical feasibility. At a typical cost of £250,000 (332,375 dollars) to £1million (1,329,500 dollars) each, the successful companies will be supported and fully funded to take their technologies through to commercialization and procurement.

Focused on effective medicines management, the current competition winners are developing innovative solutions to improve the number of patients taking prescribed medication. The three companies selected to receive phase 2 funding are:

Bespak Europe Ltd, (Cambridge, UK) , which is developing a new bolus drug delivery device using novel delivery technology.

Therakind Ltd, (London), which is developing a simple novel device that enables rapid and easy treatment of hypoglycaemia in child diabetes.

UMotif Ltd, (London), which is developing a patient-centered self-management and self-care platform with web and mobile apps that help people with Parkinson's Disease to track and manage their condition.

Source: SBRI Healthcare


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here